Summit Therapeutics, Inc. · 3 hours ago
Senior Scientist
Palo Alto, CA
Full-time
Onsite
Mid, Senior Level
$135K/yr - $160K/yr
3+ years expSummit Therapeutics Inc. is a biopharmaceutical oncology company focused on improving quality of life through innovative clinical studies. The Senior Scientist will take primary ownership of laboratory activities, driving research on the mechanism of action of ivonescimab and related bispecific antibodies, while contributing to pipeline development and cross-functional governance.
BiotechnologyHealth CareMedical DeviceTherapeutics
Responsibilities
MOA Research: Design and execute in vitro and in vivo studies, work with CROs and academic labs to elucidate the mechanism at the molecular, cellular and tumor-immune system levels. Translate the findings into a deeper understanding of therapeutic efficacy and resistance biology in different cancer indications that can guide indication expansion, rational drug combinations, and biomarker development
Pipeline Development: Design and execute experiments to create, characterize and advance the development of candidate molecules
Contribution to cross-functional governance: Produce in-depth analyses as well as executive summaries to inform internal stakeholders. Serve as the subject matter expert in cross-functional teams to facilitate decision-making. Author conference abstracts and presentations, submit manuscripts to peer-reviewed journals to share findings with the scientific and medical communities
Contribution to competitive intelligence collection: Evaluate emerging technologies, literature, and competitive landscapes to inform innovation and pipeline development
All other duties as assigned, including the maintenance of Summit research facilities
Qualification
Required
PhD with 3+ years or MS with 5+ years industry experience in Immunology, Cancer Biology, Molecular/Cellular Biology, or related fields
Demonstrated expertise and a strong publication record in immuno-oncology and/or angiogenesis biology fields
Strong technical skills in the design, execution and data analysis using wild type or genetically engineered syngeneic tumor model in mice, as well as xenogeneic/PDX tumor model in mice; using organoid systems and primary human leukocytes
Technical proficiency in design, execution and data analysis using 10+ colors flow cytometry analyzers and sorters is a must-have qualification
Strong record of scientific communication (presentations, posters/manuscripts) and cross-functional collaboration
Preferred
Candidates with additional expertise in multiplex IHC or fluorescent microscopy, single-cell RNAseq, or spatial transcriptomic technology platforms will be highly desirable
Candidates with additional skillsets in antibody screening, such as affinity measurement and reporter gene assays for target binding or blockade will also be highly preferable
Benefits
Bonus
Stock
Benefits
Other applicable variable compensation
Company
Summit Therapeutics, Inc.
Summit Mission Statement: To build a viable, long-lasting health care organization that assumes full responsibility for designing, developing, trial execution and enrollment, regulatory submission and approval, as well as successful commercialization of patient, physician, caregiver, and societal-friendly medicinal therapy intended to: improve quality of life, increase potential duration of life, and resolve serious medical healthcare needs.
201-500 employees
H1B Sponsorship
Summit Therapeutics, Inc. has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (3)
2024 (6)
2023 (1)
Funding
Current Stage
Public CompanyTotal Funding
$1.79BKey Investors
CARB-XEurofarmaBiomedical Advanced Research and Development Authority (BARDA)
2025-10-21Post Ipo Equity· $500M
2024-09-11Post Ipo Equity· $235M
2024-06-03Post Ipo Equity· $200M
Leadership Team
Manmeet Soni
Chief Operating Officer and Chief Financial Officer
Recent News
Company data provided by crunchbase